Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

This study is testing a combination of venetoclax (a targeted drug), SL-401 (a targeted therapy), and chemotherapy for patients with a rare blood cancer called blastic plasmacytoid dendritic cell neoplasm (BPDCN), to see if this combination can achieve better remission rates. **You may be eligible if...** - You are 18 or older - You have BPDCN (a rare blood cancer) confirmed by 2016 WHO criteria - You may be newly diagnosed or have relapsed/refractory disease - Your overall health is adequate (ECOG 0–2) - Your organ function (albumin, etc.) meets the study requirements **You may NOT be eligible if...** - You have not been diagnosed with BPDCN - Your organ function is too impaired for treatment - You do not meet the performance status requirements Talk to your doctor to see if this trial is right for you.